--- title: "D.A. Davidson & CO. Sells 38,578 Shares of Abbott Laboratories $ABT" type: "News" locale: "en" url: "https://longbridge.com/en/news/296694848.md" description: "D.A. Davidson & CO. reduced its stake in Abbott Laboratories (NYSE:ABT) by 20.7% during Q2, selling 38,578 shares per SEC filings. Meanwhile, Abbott reported positive developments including the commercial shipping of its Instinct glucose sensor with MiniMed’s Flex system and a multi-year UK distribution deal with HealthTab. Conversely, the company agreed to a $670 million settlement regarding infant formula litigation. Analyst sentiment remains moderately bullish, with recent upgrades and target price increases from firms like RBC, Baird, Piper Sandler, and Citigroup." datetime: "2026-08-23T07:36:51.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296694848.md) - [en](https://longbridge.com/en/news/296694848.md) - [zh-HK](https://longbridge.com/zh-HK/news/296694848.md) generator: "portal-rs" --- # D.A. Davidson & CO. Sells 38,578 Shares of Abbott Laboratories $ABT D.A. Davidson & CO. trimmed its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 20.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 148,208 shares of the healthcare product maker's stock after selling 38,578 shares during the quarter. D.A. Davidson & CO.'s holdings in Abbott Laboratories were worth $13,448,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Get **Abbott Laboratories** alerts: - Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Several other hedge funds and other institutional investors have also recently bought and sold shares of ABT. MidAtlantic Capital Management Inc. purchased a new position in shares of Abbott Laboratories in the fourth quarter worth $25,000. Cornerstone Financial Management LLC purchased a new stake in Abbott Laboratories during the 4th quarter valued at $25,000. Purpose Unlimited Inc. bought a new stake in Abbott Laboratories in the 4th quarter worth $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in shares of Abbott Laboratories in the fourth quarter valued at about $26,000. Finally, Abound Financial LLC bought a new position in shares of Abbott Laboratories during the fourth quarter valued at about $26,000. Institutional investors own 75.18% of the company's stock. ## Abbott Laboratories News Summary Here are the key news stories impacting Abbott Laboratories this week: - Positive Sentiment: Abbott’s Instinct continuous glucose sensor is now commercially shipping in the U.S. integrated with MiniMed’s Flex automated insulin-delivery system. The partnership expands Abbott’s presence in diabetes technology and could support sensor adoption and recurring revenue. MiniMed Ships MiniMed Flex With Abbott's Smallest Instinct Sensor - Positive Sentiment: Abbott also entered a multiyear agreement with HealthTab to distribute its Afinion 2 point-of-care analyzers through NHS-linked pharmacies in the United Kingdom. The deal may broaden access to Abbott’s HbA1c and lipid-testing products, although financial details were not disclosed. HealthTab Enters Multi-Year Collaboration Agreement with Abbott - Neutral Sentiment: Abbott agreed to pay approximately **$670 million** to resolve the Gill case and claims from roughly 2,000 individuals involving specialty formulas for premature infants. The settlement resolves a portion of the litigation, including the appeal of a prior $495 million verdict, reducing uncertainty and potentially avoiding additional legal costs. Abbott denied that its products cause necrotizing enterocolitis and said regulators and medical professionals consider the formulas safe and necessary. Abbott agrees to $670 million settlement of infant formula cases - Negative Sentiment: The settlement represents a significant cash and earnings cost and does not resolve all potential litigation related to the infant formulas. Investors may continue to assess the scope of remaining claims and the effect on Abbott’s legal reserves and profitability. Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas ## Analyst Ratings Changes - AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead? Several research firms recently issued reports on ABT. Royal Bank Of Canada reissued an "outperform" rating and issued a $130.00 target price on shares of Abbott Laboratories in a research note on Friday, July 17th. Robert W. Baird started coverage on Abbott Laboratories in a report on Wednesday, July 1st. They issued an "outperform" rating and a $121.00 price objective for the company. Piper Sandler reiterated an "overweight" rating and issued a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Citigroup upped their target price on Abbott Laboratories from $108.00 to $112.00 and gave the company a "buy" rating in a report on Friday, July 17th. Finally, Weiss Ratings upgraded shares of Abbott Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a report on Thursday, August 6th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Abbott Laboratories has an average rating of "Moderate Buy" and an average target price of $118.67. **Get Our Latest Analysis on Abbott Laboratories** ## Abbott Laboratories Stock Up 2.2% - Abbott Stock Crash: Rebound Could Be Coming Fast Shares of NYSE:ABT opened at $116.62 on Friday. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $201.80 billion, a price-to-earnings ratio of 37.74, a PEG ratio of 2.26 and a beta of 0.59. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The stock has a fifty day simple moving average of $100.08 and a two-hundred day simple moving average of $100.05. Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating analysts' consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $12.59 billion for the quarter, compared to analysts' expectations of $12.52 billion. During the same quarter in the prior year, the company posted $1.26 earnings per share. The business's revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, research analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year. ## Abbott Laboratories Dividend Announcement The company also recently declared a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend was Wednesday, July 15th. Abbott Laboratories's dividend payout ratio is presently 81.55%. ## Abbott Laboratories Company Profile (Free Report) Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions. In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability. ## See Also - Five stocks we like better than Abbott Laboratories - 2 Biotech Stocks Shaping Up for Major Breakouts - 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs - 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run - Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit? **Want to see what other hedge funds are holding ABT?** Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report). *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Abbott Laboratories Right Now? Before you consider Abbott Laboratories, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list. While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [ABT.US](https://longbridge.com/en/quote/ABT.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [RY.US](https://longbridge.com/en/quote/RY.US.md) - [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md) - [C.US](https://longbridge.com/en/quote/C.US.md) - [C-R.US](https://longbridge.com/en/quote/C-R.US.md) ## Related News & Research - [Xcel Wealth Management LLC Cuts Stock Holdings in Abbott Laboratories $ABT](https://longbridge.com/en/news/296700328.md) - [Abbott Laboratories $ABT Shares Purchased by Mission Wealth Management LP](https://longbridge.com/en/news/296201610.md) - [Murphy Pohlad Asset Management LLC Purchases 12,140 Shares of Abbott Laboratories $ABT](https://longbridge.com/en/news/296461096.md) - [Abbott Laboratories $ABT Holdings Increased by Merit Financial Group LLC](https://longbridge.com/en/news/296328656.md) - [Abbott settles appeal over $495 million infant formula verdict](https://longbridge.com/en/news/296386129.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**